SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    HijiyaN,HudsonMM,LensingS, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007; 297: 1207-1215.
  • 2
    PuiCH,RibeiroRC,HancockML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991; 325: 1682-1687.
  • 3
    FelixCA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol. 2001; 36: 525-535.
  • 4
    DaviesSM. Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol. 2001; 36: 536-540.
  • 5
    BlancoJG,EdickMJ,HancockML, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 2002; 12: 605-611.
  • 6
    WooMH,ShusterJJ,ChenC, et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia. 2000; 14: 232-237.
  • 7
    LarsonRA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007; 20: 29-37.
  • 8
    PaganaL,PulsoniA,TostiME, et al. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol. 2001; 112: 109-117.
  • 9
    PulsoniA,PaganoL,LoCF, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood. 2002; 100: 1972-1976.
  • 10
    HasleH. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2001; 2: 429-436.
  • 11
    MathewCG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006; 25: 5875-5884.
  • 12
    PollicardoN,O'BrienS,EsteyEH, et al. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia. 1996; 10: 27-31.
  • 13
    KushnerBH,ZauberA,TanCT. Second malignancies after childhood Hodgkin's disease. The Memorial Sloan-Kettering Cancer Center experience. Cancer. 1988; 62: 1364-1370.
  • 14
    MeadowsAT,BaumE,Fossati-BellaniF, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol. 1985; 3: 532-538.
  • 15
    MeadowsAT,ObringerAC,MarreroO, et al. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. Med Pediatr Oncol. 1989; 17: 477-484.
  • 16
    BhatiaS,RobisonLL,OberlinO, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996; 334: 745-751.
  • 17
    SchellongG,RiepenhausenM,CreutzigU, et al. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. J Clin Oncol. 1997; 15: 2247-2253.
  • 18
    CiminoG,PapaG,TuraS, et al. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol. 1991; 9: 432-437.
  • 19
    BhatiaS,KrailoMD,ChenZ, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group. Blood. 2007; 109: 46-51.
  • 20
    MahgoubN,TaylorBR,Le BeauMM, et al. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood. 1999; 93: 3617-3623.
  • 21
    ChenH,SandlerDP,TaylorJA, et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet. 1996; 347: 295-297.
  • 22
    WinickNJ,McKennaRW,ShusterJJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. 1993; 11: 209-217.
  • 23
    PuiCH,BehmFG,RaimondiSC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989; 321: 136-142.
  • 24
    Le DeleyMC,LeblancT,ShamsaldinA, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 2003; 21: 1074-1081.
  • 25
    RatainMJ,KaminerLS,BitranJD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987; 70: 1412-1417.
  • 26
    SmithMA,RubinsteinL,AndersonJR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999; 17: 569-577.
  • 27
    GombosDS,HungerfordJ,AbramsonDH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007; 114: 1378-1383.
  • 28
    KushnerBH,KramerK,CheungNK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999; 17: 3221-3225.
  • 29
    HijiyaN,GajjarA,ZhangZ, et al. Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. Leukemia. 2004; 18: 1581-1586.
  • 30
    ChenCL,FuscoeJC,LiuQ,PuiCH,MahmoudHH,RellingMV. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst. 1996; 88: 1840-1847.
  • 31
    PuiCH,RellingMV,BehmFG, et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia. 1995; 9: 1680-1684.
  • 32
    AmylonMD,ShusterJ,PullenJ, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999; 13: 335-342.
  • 33
    RellingMV. Therapeutic and pharmacokinetic considerations. In: PuiCH, ed. Treatment of Acute Leukemias: New Directions for Clinical Research.1st ed. Totowa, NJ: Humana Press, Inc; 2003: 421-427.
  • 34
    SandovalC,PuiCH,BowmanLC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol. 1993; 11: 1039-1045.
  • 35
    Pedersen-BjergaardJ,PhilipP,LarsenSO, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in 7 cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia. 1993; 7: 1975-1986.
  • 36
    KushnerBH,CheungNK,KramerK,HellerG,JhanwarSC. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol. 1998; 16: 3880-3889.
  • 37
    BarnardDR,LangeB,AlonzoTA, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood. 2002; 100: 427-434.
  • 38
    MontesinosP,GonzalezJD,RayonC, et al. Secondary acute myeloid leukemia and myelodysplastic syndrome following ATRA and anthracycline monochemotherapy treatment for acute promyelocytic leukemia [abstract]. Blood. 2007; 110: 544a.
  • 39
    Le DeleyMC,SuzanF,CutuliB, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007; 25: 292-300.
  • 40
    SasoR,KulkarniS,MitchellP, et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer. 2000; 83: 91-94.
  • 41
    LinassierC,BarinC,CalaisG, et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol. 2000; 11: 1289-1294.
  • 42
    ChaplainG,MilanC,SgroC,CarliPM,Bonithon-KoppC. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol. 2000; 18: 2836-2842.
  • 43
    SeiterK,FeldmanEJ,SreekantaiahC, et al. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia. 2001; 15: 963-970.
  • 44
    TebbiCK,LondonWB,FriedmanD, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007; 25: 493-500.
  • 45
    BarryEV,VroomanLM,DahlbergSE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008; 26: 1106-1111.
  • 46
    RellingMV,BoyettJM,BlancoJG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood. 2003; 101: 3862-3867.
  • 47
    HershmanD,NeugutAI,JacobsonJS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007; 99: 196-205.
  • 48
    PattDA,DuanZ,FangS,HortobagyiGN,GiordanoSH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007; 25: 3871-3876.
  • 49
    SmithRE,BryantJ,DeCillisA,AndersonS. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 2003; 21: 1195-1204.
  • 50
    OffmanJ,OpelzG,DoehlerB, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004; 104: 822-828.
  • 51
    FriedmanDL,LeisenringW,SchwartzJL,DeegHJ. Second malignant neoplasms following hematopoietic stem cell transplantation. Int J Hematol. 2004; 79: 229-234.
  • 52
    HakeCR,GraubertTA,FenskeTS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant. 2007; 39: 59-70.
  • 53
    KrishnanA,BhatiaS,SlovakML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000; 95: 1588-1593.
  • 54
    LenzG,DreylingM,SchiegnitzE, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol. 2004; 22: 4926-4933.
  • 55
    MicallefIN,LillingtonDM,ApostolidisJ, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000; 18: 947-955.
  • 56
    RellingMV,YanishevskiY,NemecJ, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia. 1998; 12: 346-352.
  • 57
    FelixCA,WalkerAH,LangeBJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA. 1998; 95: 13176-13181.
  • 58
    AllanJM,WildCP,RollinsonS, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA. 2001; 98: 11592-11597.
  • 59
    LarsonRA,WangY,BanerjeeM, et al. Prevalence of the inactivating 609C->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999; 94: 803-807.
  • 60
    SeedhouseC,FaulknerR,AshrafN,Das-GuptaE,RussellN. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res. 2004; 10: 2675-2680.
  • 61
    LeoneG,PaganoL,Ben YehudaD,VosoMT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007; 92: 1389-1398.
  • 62
    YeohEJ,RossME,ShurtleffSA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002; 1: 133-143.
  • 63
    HartfordC,YangW,ChengC, et al. Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia. 2007; 21: 2128-2136.
  • 64
    BeaumontM,SanzM,CarliPM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003; 21: 2123-2137.
  • 65
    WeintraubM,Revel-VilkS,CharitM,AkerM,Pe'erJ. Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma. J Pediatr Hematol Oncol. 2007; 29: 646-648.
  • 66
    KernW,HaferlachT,SchnittgerS,HiddemannW,SchochC. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol. 2004; 22: 2510-2511.
  • 67
    HaleGA,HeslopHE,BowmanLC, et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant. 1999; 24: 735-739.
  • 68
    LeaheyAM,FriedmanDL,BuninNJ. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplant. 1999; 23: 21-25.
  • 69
    SandlerES,FriedmanDJ,MustafaMM,WinickNJ,BowmanWP,BuchananGR. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer. 1997; 79: 1049-1054.
  • 70
    Surveillance Research Program, National Cancer Institute. SEER 9, 1990-2004, MP-SIR event analysis event record frequencies. SEER*Stat software, version 6.3.6 (available at: www.seer.cancer.gov/seerstat [access date]); Surveillance, Epidemiology, and End Results (SEER) Program (available at: www.seer.cancer.gov [access date]); and SEER*Stat Database: Incidence-SEER 17 Registries, Limited-Use, November 2006 Submission (1973-2004 varying)—Linked to County Attibutes-Total US, 1969-2004 Counties. Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2007 (based on the November 2006 submission. 2006).
  • 71
    Surveillance Research Program, National Cancer Institute. Overall period survival 2003—ALL and AML Children <20 years allowing multiple primaries. SEER/Stat software, version 6.3.6 (available at: www.seer.cancer.gov/seerstat [access date]); Surveillance, Epidemiology, and End Results (SEER) Program (available at: www.seer.cancer.gov [access date]); and SEER*Stat Database: Incidence-SEER 17 Registries, Limited-Use, November 2006 Submission (1973-2004 varying)—Linked to County Attibutes-Total US, 1969-2004 Counties. Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2007 (based on the November 2006 submission).
  • 72
    SchochC,KernW,SchnittgerS,HiddemannW,HaferlachT. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004; 18: 120-125.
  • 73
    PulsoniA,PaganoL. Treatment of secondary acute myeloid leukemia. J Clin Oncol. 2005; 23: 926-927.
  • 74
    ChangC,StorerBE,ScottBL, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007; 110: 1379-1387.
  • 75
    LarsonRA. Etiology and management of therapy-related myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2007; 2007: 453-459.
  • 76
    PuiCH,EvansWE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354: 166-178.
  • 77
    GaynonPS,TriggME,HeeremaNA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000; 14: 2223-2233.
  • 78
    MorickeA,ReiterA,ZimmermannM, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111: 4477-4489.
  • 79
    PuiCH,BoyettJM,RiveraGK, et al. Long-term results of Total Therapy Studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia. 2000; 14: 2286-2294.
  • 80
    PuiCH,SandlundJT,PeiD, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004; 104: 2690-2696.
  • 81
    VilmerE,SuciuS,FersterA, et al. Long-term results of 3 randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2000; 14: 2257-2266.
  • 82
    HarmsDO,Janka-SchaubGE. Co-Operative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL): long-term follow-up of Trials 82, 85, 89 and 92. Leukemia. 2000; 14: 2234-2239.
  • 83
    TsuchidaM,IkutaK,HanadaR, et al. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995. Leukemia. 2000; 14: 2295-2306.
  • 84
    SchrappeM,ReiterA,ZimmermannM, et al. Long-term results of 4 consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000; 14: 2205-2222.
  • 85
    GustafssonG,SchmiegelowK,ForestierE, et al. Improving outcome through 2 decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia. 2000; 14: 2267-2275.
  • 86
    EdenOB,HarrisonG,RichardsS, et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia. 2000; 14: 2307-2320.
  • 87
    KampsWA,VeermanAJ,van WeringER,van WeerdenJF,SlaterR,van der Does-van den BergA. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia. 2000; 14: 2240-2246.
  • 88
    ConterV,AricoM,ValsecchiMG, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia. 2000; 14: 2196-2204.
  • 89
    MaloneyKW,ShusterJJ,MurphyS,PullenJ,CamittaBA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia. 2000; 14: 2276-2285.
  • 90
    National Cancer Institute, Surveillance Research Program. SEER*Stat software version 6.3.6 (available at: www.seer. cancer.gov/seerstat [access date]); Surveillance Epidemiology, and End Results (SEER) Program (available at: www. seer.cancer.gov [access date]); and SEER/Stat Database: Incidence-SEER 17 Registries, Limited-Use, November 2006 submission (1973-2004 varying)—Linked to County Attributes-Total US, 1969-2004 Counties. Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2007 (based on the November 2006 submission).
  • 91
    ZunaJ,CaveH,EckertC, et al. Childhood secondary ALL after ALL treatment. Leukemia. 2007; 21: 1431-1435.
  • 92
    GeethaN,SreedeviAmmaN,KusumakumaryP,LaliVS,NairMK. Acute lymphoblastic leukemia occurring as a second malignancy: report of a case and review of literature. Pediatr Hematol Oncol. 1999; 16: 267-270.
  • 93
    HungerSP,SklarJ,LinkMP. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of 3 cases and review of the literature. J Clin Oncol. 1992; 10: 156-163.
  • 94
    SzezepanskiT,van der VeldenVHJ,Van VlierberghePV, et al. Late relapses of childhood T-ALL are frequently second T-ALL [abstract]. Blood. 2007; 110: 430a.
  • 95
    PuiCH,RellingMV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol. 2000; 109: 13-23.
  • 96
    TravisLB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2020-2026.
  • 97
    BogniA,ChengC,LiuW, et al. Genome-wide approach to identify risk factors for therapy-related myeloid leukemia. Leukemia. 2006; 20: 239-246.
  • 98
    FelixCA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta. 1998; 1400: 233-255.
  • 99
    CroninK,MariottoA,ScoppaS,GreenD,CleggL. Differences between Brenner et al. and NCI methods for calculating period survival. Statistical Research and Applications Branch, National Cancer Institute. Technical Report 2003-02-A. Available at: http://srab.cancer.gov/reports. [Access date, 2008].